RICHARD ALDRICH
CIK 1185039 · last filed 2023-03-06
RICHARD ALDRICH is a corporate insider who has filed 101 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for CNCE, was dated Mar 6, 2023. Across all open-market trades the lifetime net is +$22.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $80.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$80.27M
12
101
$22.50M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | 0 | $8.37 | $0 | -$1.19M | 20 | 2023-03-06 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | 4,687 | $15.90 | $74.5K | $0 | 1 | 2018-12-11 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 934,484 | $27.00 | $25.23M | $4.87M | 5 | 2018-10-05 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 69,552 | — | — | $8.55M | 37 | 2018-10-02 |
| PTCT | Director | 1,050,104 | $74.84 | $78.59M | $11.11M | 5 | 2015-06-10 |
| VSTM | Director | 273,081 | $6.09 | $1.66M | $270.2K | 23 | 2013-11-12 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | 10%+ Owner | 690,309 | — | — | $6.69M | 4 | 2008-11-14 |
| SEQUENOM INC (SQNM) Delisted | 10%+ Owner | 5,872,966 | — | — | $0 | 1 | 2008-07-14 |
| CRIS | 10%+ Owner | 3,125 | $4.97 | $15.5K | -$9.10M | 1 | 2008-04-17 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 189,210 | — | — | $1.30M | 1 | 2008-01-16 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 38,095 | — | — | $0 | 1 | 2007-05-31 |
| LIPID SCIENCES INC/ (LIPD) Delisted | 10%+ Owner | 3,713,962 | — | — | $1.7K | 1 | 2007-03-28 |
Recent Filings
101 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-06 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Mixed | −613,377 | $0 | EDGAR |
| 2022-06-13 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | +16,400 | $0 | EDGAR |
| 2022-06-06 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Buy (P) | +210,526 | $1000.0K | EDGAR |
| 2021-06-11 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | +5,125 | $0 | EDGAR |
| 2020-06-12 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-17 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-12-11 | Tempest Therapeutics, Inc. (MLND) Delisted | Grant (A) | +755 | $0 | EDGAR |
| 2018-11-15 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Buy (P) | +50,000 | $591.3K | EDGAR |
| 2018-10-05 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-02 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +14,558 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.